Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Interrogating the role of m6A mRNA methylation in the aging of the β-cell and diabetes

Award Number: K99DK135927
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 05/01/2023
PERIOD OF PERFORMANCE END DATE: 04/30/2025

Group Awards By:

View Award Description

Interrogating the role of m6A mRNA methylation in the aging of the β-cell and diabetes - PROJECT SUMMARY Although the etiopathogenesis of Type 1 (T1D) and Type 2 diabetes (T2D) is different, decreased functional β-cell mass is a central feature in both diseases. Concerted research efforts aim at developing strategies to improve β-cell survival and restore β-cell function in patients with diabetes. Cellular senescence is a major hallmark of aging. Recent work has demonstrated that β-cell senescence is a common contributor to Type 1 diabetes (T1D) and Type 2 diabetes (T2D). RNA modifications are emerging as important modulators of many hallmarks of aging. We have discovered that m6A mRNA methylation is essential for β-cell function and survival, and recently characterized the m6A landscape of human T1D and T2D islets. Our preliminary data shows that the m6A eraser ALKBH5 is upregulated in aged human β-cells and differentially m6A methylated genes in T1D and T2D are enriched for DNA damage response and senescence pathways compared to controls. The goal of this application is to use state-of-the art methods to characterize the m6A methylome of the aging β- cell and identify m6A-regulated pathways that underlie the accelerated β-cell senescence in diabetes. I will test the overarching hypothesis that aging β-cells exhibit transcript-specific m6A hypomethylation and consequent upregulation of mRNAs involved in driving cell senescence, and that m6A is therefore a valuable therapeutic target for diabetes. In Specific Aim 1, I will characterize the temporal m6A landscape of the aging β-cell. Completion of Aim 1, which will take place during K99 phase, will provide me with training in aspects of aging biology and further experience with bioinformatics analysis of m6A data necessary to independently complete the R00 phase and future R01 submissions. In Specific Aim 2, which will span the K99 and R00 phases, I will identify the molecular targets of ALKBH5 in the human β-cell transition to senescence. Completion of the sub- aim of Aim 2 proposed during the K99 phase will provide me with the training in photoactivatable ribonucleoside- enhanced crosslinking and immunoprecipitation (PAR-CLIP) sequencing and data analysis necessary to complement Aim 1, and independently complete Aim 2 during the R00 phase. For Specific Aim 3, I will target m6A levels to reduce β-cell senescence and improve diabetes in vivo. Completion of this aim will allow me to validate candidate genes identified in Aim’s 1 and 2 and to test in vivo the role of Alkbh5 in driving the accelerated senescence seen in β-cells in diabetes. These experiments are novel as they combine omics-based approaches, mouse genetic models, physiology, and molecular biology to examine the mechanistic role of m6A, and particularly ALKBH5, in β-cell senescence transition in diabetes.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	3/16/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $90,000 )
2024	2024	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	5/1/2024	NON-COMPETING CONTINUATION	$90,000
														Subtotal = $90,000

Issue Date FY: 2023 ( Subtotal = $90,000 )
2023	2023	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	4/20/2023	NEW	$90,000
														Subtotal = $90,000

Grand Total All Awards = $180,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Interrogating the role of m6A mRNA methylation in the aging of the β-cell and diabetes

Award Number: K99DK135927

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 05/01/2023

PERIOD OF PERFORMANCE END DATE: 04/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer